Docetaxel in Breast Cancer
NCT00312208
Completed
Primary objective : * To compare disease-free survival after treatment with docetaxel in combination with doxorubicin and cyclophosphamide to doxorubicin and cyclophosphamide followed by docetaxel in operable adjuvant breast cancer HER2neu negative patients with positive axillary lymph nodes. Secondary objectives : * To compare toxicity and quality of life between the 2 above-mentioned arms. * To evaluate pathologic and molecular markers for predicting efficacy.
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
12/04/2013
Locations: Sanofi-Aventis, Bridgewater, New Jersey +36 locations
Conditions: Breast Cancer
Register for Updates
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
NCT00005959
Unknown
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug with rituximab may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of rituximab plus combination chemotherapy in treating patients who have intermedi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2013
Locations: Montgomery Cancer Center, Montgomery, Alabama +26 locations
Conditions: Lymphoma
Register for Updates
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00005960
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have prostate cancer that has not responded to hormone therapy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/03/2013
Locations: Wilshire Oncology Medical Group, Inc., Los Angeles, California +5 locations
Conditions: Pain, Prostate Cancer
Register for Updates
Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma
NCT00017290
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill cancer cells. It is not yet known which regimen of chemotherapy combined with vaccine therapy is more effective for non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to determine the effectiveness of combination chemotherapy followed by vaccine therapy plus sargramostim in treating patients who have stage I... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2013
Locations: SuperGen, Incorporated, Dublin, California +23 locations
Conditions: Lymphoma
Register for Updates
Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)
NCT00750815
Completed
Cyclophosphamide is a chemotherapy agent with known activity in myeloma. The new regimen that we will test in this study is called CVDD and contains Cyclophosphamide with Bortezomib (VELCADE), Pegylated Liposomal Doxorubicin (DOXIL®, PLD), and Dexamethasone (VDD). The purpose of this study is to determine if the addition of another type of chemotherapy agent, Cyclophosphamide, to the regimen VDD (CVDD) is well tolerated and improves response rates in myeloma. We will also find the highest safe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2013
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Multiple Myeloma
Register for Updates
Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer
NCT00121134
Completed
The purpose of this research study is to study the effects (good and bad) of bevacizumab alone, bevacizumab with low-dose continuous chemotherapy (called metronomic chemotherapy), or bevacizumab with capecitabine, on you and your cancer. The goals of the study will be to: * Examine the safety of these drugs * See how easy or difficult it is to be treated with them * Monitor for any signs of recurrent cancer * Look at blood markers that might indicate how the treatment is working
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2013
Locations: University of California, San Francisco, San Francisco, California +4 locations
Conditions: Breast Cancer
Register for Updates
High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment
NCT01679041
Terminated
The purpose of this study is to evaluate the toxicity and the effectiveness of high dose chemotherapy with HPC transplant Multiple Sclerosis that has failed at least two lines of therapy
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
11/21/2013
Locations: Amarillo Diagnostic Clinic, Amarillo, Texas +2 locations
Conditions: Multiple Sclerosis
Register for Updates
ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer
NCT00496665
Completed
The purpose of this research study is to determine the safety and tolerability of the combination of Zactima with metronomic chemotherapy. Zactima is an oral anti-angiogenesis drug, which means it fights cancer by cutting off a tumor's blood supply. Thus, the drug starves the tumor by preventing the delivery of nutrients and oxygen. Metronomic chemotherapy is low dose oral chemotherapy pills which are taken daily. Unlike traditional chemotherapy, metronomic chemotherapy is thought to fight cance... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2013
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer
NCT00002482
Unknown
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody and cyclophosphamide in treating patients with metastatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2013
Locations: St. Vincent Medical Center - Los Angeles, Los Angeles, California
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
NCT00093587
Unknown
RATIONALE: Giving chemotherapy and total-body irradiation before a donor bone marrow transplant or peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an im... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
11/05/2013
Locations: Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California
Conditions: Graft Versus Host Disease, Leukemia
Register for Updates
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer
NCT00782379
Completed
RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and cyclophosphamide, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
10/28/2013
Locations: Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia
Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes
Register for Updates
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
NCT00818961
Terminated
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving a monoclonal antibody, such as alemtuzumab,... Read More
Gender:
ALL
Ages:
Between 40 years and 72 years
Trial Updated:
10/28/2013
Locations: Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia
Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Register for Updates